Skye Bioscience Incis A Clinical Stage Biotechnology Company Based In San Diegocaliforniathe Company Focuses On Developing Innovative Therapeutics For Metabolic Diseasesparticularly Obesityby Modulating The Endocannabinoid Systemskye Bioscience Is Advancing Its Lead Productnimacimaba Monoclonal Antibody That Targets Peripheral Cb1 Receptorsthis Treatment Aims To Provide Effective Weight Loss Solutions While Minimizing Neuropsychiatric Side Effects Associated With Previous Therapies Nimacimab Is Currently In A Phase 2 Trialevaluating Its Efficacy In Weight Loss And Metabolic Healththe Company Is Also Exploring Combination Therapies To Enhance Treatment Outcomesskye Bioscience Positions Nimacimab As A Potential Alternative To Existing Glp 1 Based Therapiestargeting Patients Who Need Sustainable Weight Loss With Improved Safety Profilesthe Obesity Drug Market Presents Significant Opportunitiesand Skye Is Actively Participating In Clinical Trials And Industry Conferences To Advance Its Mission In Metabolic Health
